The NHS has become the first healthcare system in Europe to widely roll out a revolutionary take home tablet for multiple sclerosis patients that requires just 20 days of treatment spread over four years. Cladribine offers a life changing alternative to existing therapies that involve regular hospital infusions, frequent self injections, and extensive monitoring that keep patients tethered to medical facilities. Approved by NICE for patients with active relapsing remitting MS, the convenient tablet provides comparable clinical benefits while dramatically reducing hospital visits and freeing patients to live their lives with greater independence.
Nearly 80 percent of patients taking cladribine experienced no relapses during clinical trials, which also revealed a stunning reduction of 7.5 times fewer new brain lesions compared to those on placebo. The treatment is especially beneficial for patients planning families, as its short course regimen over two years allows safe conception in years three and four of the treatment cycle. An estimated 2,000 patients will be offered this groundbreaking treatment over the first three years, saving thousands of clinical hours annually while improving quality of life for people living with MS. This rollout demonstrates the NHS’s commitment to adopting innovative treatments that shift care out of hospitals and into communities, giving patients more freedom while maximizing healthcare productivity.
